Compare iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ Inv Grade Corporate Bond ETF vs Twist Bioscience Corp — how do they compare? iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $106.84, while Twist Bioscience Corp trades at $94.58 (market cap $5.45B). The key difference: Twist Bioscience Corp is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| LQD | TWST | |
|---|---|---|
52-Week High | $112.91 | $102.88 |
52-Week Low | $106.96 | $24.16 |
Market Cap | — | $5.45B |
Sector | — | Health |
Enterprise Value | — | $5.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LQD trades at $107.15, down 0.38% with a bearish technical signal from moving averages. Recent dividend payments include $0.42 in May 2026 and $0.41 in June 2026, reflecting steady income distribution. The fixed income ETF sector shows renewed investor interest amid economic resilience and rate uncertainty, as noted by ETF Trends on July 14, 2026.
Outlook remains cautious due to technical weakness and Federal Reserve policy risks. Opportunities exist for income-focused investors seeking corporate bond exposure, but rising rate expectations pose headwinds. Key risks include inflation persistence and narrowing market breadth impacting bond valuations.
Twist Bioscience (TWST) trades at $87.41, down 6.86% today, with a bullish technical outlook despite recent earnings misses. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a -19.85% net margin. Analyst consensus is strongly bullish with 11 buy ratings and a $91.63 price target, while recent news highlights AI-driven drug discovery collaborations and upcoming Q3 earnings.
The stock presents growth potential through expanding synthetic biology applications and AI partnerships, but carries significant risk from persistent losses, negative cash flow, and high valuation multiples (P/S 13.94). Investors should weigh the company's innovation trajectory against its path to profitability amid competitive biotech pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
